



A novel approach for the screening of E-cigarette aerosols using an Ames whole aerosol assay

David Thorne

CORESTA SSPT

ST64

Kitzbühel, Austria 2017


Oct 9th – 12th



- Background
- Assessing the risk profile of e-cigarettes
- Whole aerosol assessment of e-cigarettes (AMES)
- Conclusions

E-cigarettes have evolved rapidly





In the UK there is a growing consensus on e-cigarette harm reduction potential





Kevin Fenton, Public Health Director of Health and Wellbeing: "The wider body of evidence consistently finds that e-cigarettes are less harmful than smoking"

E-cigarettes: an evidence update

"The current best estimate is that
e-cigarettes are around 95% less
harmful than smoking"



Nicotine without smoke: tobacco harm reduction Promote e-cigarettes widely as substitute for smoking says new RCP report



Electronic cigarettes (also known as vapourisers)
"Compared to tobacco products, electronic cigarettes are significantly safer"

Document not peer-reviewed by CORESTA

BAT's approach to e-cigarette assessment

eLiquid + Device = Product

eLiquid

What's in the liquid?

Device

What's the device made of?

Does it conform to electrical safety?

Product

What's in the vapour?

How stable is the product over time?

How is it used?

BAT's approach to e-cigarette assessment

In vitro

01

EMISSIONS

- Untargeted emissions
- Targeted emissions
- Environmental emissions

02

EXPOSURE

- Puffing behaviour
- Average daily consumption
- Clinical PK
- Clinical BoE

03

RISK

- Clinical BoBE
- Risk perception
- Post market surveillance

in vitro reg tox


in vitro disease models

in vitro systems science

Classical regulatory toxicology –TPM

BRITISH AMERICAN TOBACCO

OECD TG 471: Bacterial Reverse Mutation Test S. typhimurium TA98 & TA100




Exposure to reference cigarette smoke caused mutations in a dose dependent manner; e-cigarettes gave no response*


Irritancy assessment of aerosols

Comparison of cytotoxicity after cigarette and e-cigarette exposure using EpiAirway





No cytotoxicity with e-cigarette in EpiAirway cultures*



*These qualities do not necessarily mean this product produces less adverse health effects than tobacco products


RICAN O

Comparing transcriptional perturbations in MucilAir




48, 854 genes/ RNA features screened

3R4F 8197 significant genes/RNA features Vype ePen 49 significant genes/RNA features Vype ePen* 113 significant genes/RNA features



Toxicogenomics – RNA-seq differential gene expression*

RNA-seq data mapped onto 131 pathway-focussed gene sets with specific biological function and disease processes



Gene enrichment analysis: heatmap indicating fold change for RNAs significant at pFDR<0.05

*These qualities do not necessarily mean this product produces less adverse health effects than tobacco products





How do you confirm a negative response?




"The wider body of evidence consistently finds that e-cigarettes are less harmful than smoking"

"The current best estimate is that e-cigarettes are around 95% less harmful than smoking"

Experimental Design

Study Outline





317 - Document not peer-reviewed by CORESTA

Experimental Design

Product



Product	Description	Aerosol Generation	Standardised Method for Aerosol Generation
yes for E and	A closed system vaping device (Vype ePen, 18mg/ml Blended Tobacco)	Aeroionisation of an e-liquid formulation	CORESTA regime (CR81) [*] 55 ml puff volume; 3 sec puff duration; 30 sec interval between puff Square Wave puff profile

^{*} CORESTA Recommended Method No 81, 2015. Routine analytical machine for e-cigarette aerosol generation and collection – Definitions and Standard Conditions. CRM No 81, 2015.


BRITISH AMERICAN

TOBACCO


SSPT2017 - Document not peer-reviewed by CORESTA

Experimental Design

Exposure set up - Diluted vs. Undiluted



[A] Under standard operating parameters, the generated aerosol is delivered to the dilution system, where an airflow (L/min) is added to the aerosol to create a diluted aerosol stream. Under a negative pressure (vacuum, mL/min) a portion of the aerosol stream is drawn into the exposure module. Under standard conditions, only a small portion of the total generated aerosol reaches the biological surface.




[B] In a modified approach, the VC 10 was adapted to significantly increase exposure conditions using an undiluted aerosol stream that is transferred in its totality to the exposure module. To achieve this, the two diluting air ports and the exhaust port were deliberately blocked (X) and the vacuum disabled, the resulting undiluted aerosol was forced entirely into the exposure module under positive pressure.

Dosimetry assessment of the two dilution techniques

TOBACCO

Dose clarification



[a] Vype ePen nicotine delivery to the module using both diluted (1 L/min) and undiluted techniques assessing positional variability


[b] Mean comparison of Vype ePen nicotine delivery to the module using both diluted and undiluted techniques. The difference in deposited nicotine per puff between diluted and undiluted techniques is 11.5-fold


The Data


TA98 and TA100 after 0 - 900 puffs from an e-cigarette




UTC = untreated control 0 puff = air control B[a]P = benzo[a]pyrene 2NF= 2-nitrofluorene AAN = 2-aminoanthracene NaN3 = sodium azide










Average puffs per day $^{\sim}163 \pm 138$ puffs per day 99% of users puffed less than 560 puffs per day


The Data

TA97, E.coli, TA104 - Screening approach?





UTC = untreated control
0 puff = air control
B[a]P = benzo[a]pyrene
2NF= 2-nitrofluorene
AAN = 2-aminoanthracene
NaN3 = sodium azide
NQO = 4-nitroquinoline 1-oxide



SUMMARY

- Demonstrated a new way of utilising and conducting WA exposures, linked to human consumption and maximising dose
- Despite extreme whole aerosol exposure, up to 900 puffs, mutagenicity was not observed in any strain
- Pre-clinical assessment shows that e-cigarettes have the potential to reduce risk relative to cigarettes
- We have confirmed a negative!
- Data currently under Review in Mutation research (Peer-Review Comments)



Thank You and Acknowledgements

BAT R&D			COVANCE
Annette Dalrymple	Clive Meredith	James Murphy	Michael Hollings
Jason Adamson	Emmanuel Minet	Marianna Gaça	<u>Adam Seymour</u>
Chris Proctor	Andrew Baxter	Simone Santopietro	Mark Ballantyne
Damien Breheny	David Azzopardi	Ian Crooks	Julie Clements
Ivan Verrastro	Sarah Corke	Tomasz Jaunky	





©British American Tobacco (Investments) Limited 2017. All rights reserved. No part of these materials may be reproduced in any form or by any means without the prior written consent of British American Tobacco (Investments) Limited and no responsibility or liability is accepted for any third party reliance on any data contained herein. The data and information used in these materials has been compiled from a number of sources.